Wyeth and Progenics Begin Phase II Trial of Oral Methylnaltrexone

September 1, 2006

Wyeth Pharmaceuticals and Progenics Pharmaceuticals, Inc. (Tarrytown, New York) have begun a phase II clinical trial to evaluate once-daily dosing of oral methylnaltrexone, a peripheral mu opioid-receptor antagonist designed to reverse the effect of opioids on opioid receptors outside the central nervous system, thus reducing opioid-induced constipation. The trial is designed to identify the dose(s) of methylnaltrexone to be taken forward into the phase III studies.

MADISON, New Jersey—Wyeth Pharmaceuticals and Progenics Pharmaceuticals, Inc. (Tarrytown, New York) have begun a phase II clinical trial to evaluate once-daily dosing of oral methylnaltrexone, a peripheral mu opioid-receptor antagonist designed to reverse the effect of opioids on opioid receptors outside the central nervous system, thus reducing opioid-induced constipation. The trial is designed to identify the dose(s) of methylnaltrexone to be taken forward into the phase III studies.